Activation of the S100A7/RAGE Pathway by IGF-1 Contributes to Angiogenesis in Breast Cancer.
Maria Grazia MuoioMarianna TaliaRosamaria LappanoAndrew H SimsVeronica VellaFrancesca CirilloLivia ManzellaMarika GiulianoMarcello MaggioliniErnestina Marianna De FrancescoErnestina Marianna De FrancescoPublished in: Cancers (2021)
In ER-positive BCs the IGF-1 dependent activation of the S100A7/RAGE signaling in adjacent endothelial cells may serve as a previously unidentified angiocrine effector. Targeting S100A7 may pave the way for a better control of BC, particularly in conditions of unopposed activation of the IGF-1/IGF-1R axis.